ScholarLens Back to search
2022•Annals of HematologyOpen access

Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey

Mehmet Sinan Dal, Bahar Uncu Ulu, Ant Uzay, Olga Meltem Akay, Sevgi Kalayoğlu Beşışık, Mustafa Nuri Yenerel, Serhat Çelik, Leylagül Kaynar, Orhan Kemal Yücel, Burak Devecı, Mehmet Sönmez, Özgür Mehtap, Hüseyin Saffet Beköz, Cenk Sunu, Ozan Salim, Turgay Ulaş, Sami Kartı, Fevzi Altuntaş, Burhan Ferhanoğlu, Tülin Fırat Tuğlular

Open full text 12 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

Open-access reader

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 12 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Bendamustine, Rituximab, Medicine, Internal medicine, Lymphoma, Refractory (planetary science), Hematology, Oncology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey — Research Paper | ScholarLens